Article
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.
Journal of the National Cancer Institute - 1 Jul 2016
Sabbatino Francesco, Wang Yangyang, Scognamiglio Giosuè, Favoino Elvira, Feldman Steven A, Villani Vincenzo, Flaherty Keith T, Nota Sjoerd, Giannarelli Diana, Simeone Ester, Anniciello Anna M, Palmieri Giuseppe, Pepe Stefano, Botti Gerardo, Ascierto Paolo A, Ferrone Cristina R, Ferrone Soldano
Abstract excerpt
BACKGROUND: BRAF(V600E)-mediated MAPK pathway activation is associated in melanoma cells with IFNAR1 downregulation. IFNAR1 regulates melanoma cell sensitivity to IFNα, a cytokine used for the adjuvant treatment of melanoma. These findings and the limited therapeutic efficacy of BRAF-I prompted us to examine whether the efficacy of IFNα therapy of BRAF(V600E) melanoma can be increased by its combination with...
Topics
- Animals
- Antineoplastic Combined Chemotherapy Protocols
- Apoptosis
- Cell Line, Tumor
- Cell Proliferation
- Down-Regulation
- Female
- Flow Cytometry
- Gene Expression Regulation, Neoplastic